These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 20976216)

  • 1. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.
    Giampà C; Laurenti D; Anzilotti S; Bernardi G; Menniti FS; Fusco FR
    PLoS One; 2010 Oct; 5(10):e13417. PubMed ID: 20976216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.
    Leuti A; Laurenti D; Giampà C; Montagna E; Dato C; Anzilotti S; Melone MA; Bernardi G; Fusco FR
    Neurobiol Dis; 2013 Apr; 52():104-16. PubMed ID: 23220622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease.
    Harada A; Suzuki K; Kimura H
    J Pharmacol Exp Ther; 2017 Jan; 360(1):75-83. PubMed ID: 27811172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease.
    Kleiman RJ; Kimmel LH; Bove SE; Lanz TA; Harms JF; Romegialli A; Miller KS; Willis A; des Etages S; Kuhn M; Schmidt CJ
    J Pharmacol Exp Ther; 2011 Jan; 336(1):64-76. PubMed ID: 20923867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6/2 and BACHD mouse models of Huntington's disease.
    Miller S; Hill Della Puppa G; Reidling J; Marcora E; Thompson LM; Treanor J
    J Huntingtons Dis; 2014; 3(4):333-41. PubMed ID: 25575954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.
    Giampà C; Middei S; Patassini S; Borreca A; Marullo F; Laurenti D; Bernardi G; Ammassari-Teule M; Fusco FR
    Eur J Neurosci; 2009 Mar; 29(5):902-10. PubMed ID: 19291221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
    Hebb AL; Robertson HA; Denovan-Wright EM
    Neuroscience; 2004; 123(4):967-81. PubMed ID: 14751289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease.
    Niccolini F; Haider S; Reis Marques T; Muhlert N; Tziortzi AC; Searle GE; Natesan S; Piccini P; Kapur S; Rabiner EA; Gunn RN; Tabrizi SJ; Politis M
    Brain; 2015 Oct; 138(Pt 10):3016-29. PubMed ID: 26198591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice.
    Hebb AL; Robertson HA; Denovan-Wright EM
    Eur Neuropsychopharmacol; 2008 May; 18(5):339-63. PubMed ID: 17913473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.
    Siuciak JA; Chapin DS; Harms JF; Lebel LA; McCarthy SA; Chambers L; Shrikhande A; Wong S; Menniti FS; Schmidt CJ
    Neuropharmacology; 2006 Aug; 51(2):386-96. PubMed ID: 16780899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease Models.
    Beaumont V; Zhong S; Lin H; Xu W; Bradaia A; Steidl E; Gleyzes M; Wadel K; Buisson B; Padovan-Neto FE; Chakroborty S; Ward KM; Harms JF; Beltran J; Kwan M; Ghavami A; Häggkvist J; Tóth M; Halldin C; Varrone A; Schaab C; Dybowski JN; Elschenbroich S; Lehtimäki K; Heikkinen T; Park L; Rosinski J; Mrzljak L; Lavery D; West AR; Schmidt CJ; Zaleska MM; Munoz-Sanjuan I
    Neuron; 2016 Dec; 92(6):1220-1237. PubMed ID: 27916455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conditioned medium from amniotic cells protects striatal degeneration and ameliorates motor deficits in the R6/2 mouse model of Huntington's disease.
    Giampà C; Alvino A; Magatti M; Silini AR; Cardinale A; Paldino E; Fusco FR; Parolini O
    J Cell Mol Med; 2019 Feb; 23(2):1581-1592. PubMed ID: 30585395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease.
    Giampà C; Patassini S; Borreca A; Laurenti D; Marullo F; Bernardi G; Menniti FS; Fusco FR
    Neurobiol Dis; 2009 Jun; 34(3):450-6. PubMed ID: 19281846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase-10A Inverse Changes in Striatopallidal and Striatoentopeduncular Pathways of a Transgenic Mouse Model of
    D'Angelo V; Castelli V; Giorgi M; Cardarelli S; Saverioni I; Palumbo F; Bonsi P; Pisani A; Giampà C; Sorge R; Biagioni S; Fusco FR; Sancesario G
    J Neurosci; 2017 Feb; 37(8):2112-2124. PubMed ID: 28115486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET imaging shows loss of striatal PDE10A in patients with Huntington disease.
    Ahmad R; Bourgeois S; Postnov A; Schmidt ME; Bormans G; Van Laere K; Vandenberghe W
    Neurology; 2014 Jan; 82(3):279-81. PubMed ID: 24353339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation.
    Threlfell S; Sammut S; Menniti FS; Schmidt CJ; West AR
    J Pharmacol Exp Ther; 2009 Mar; 328(3):785-95. PubMed ID: 19056933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease.
    Giampà C; Montagna E; Dato C; Melone MA; Bernardi G; Fusco FR
    PLoS One; 2013; 8(5):e64037. PubMed ID: 23700454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.
    Schmidt CJ; Chapin DS; Cianfrogna J; Corman ML; Hajos M; Harms JF; Hoffman WE; Lebel LA; McCarthy SA; Nelson FR; Proulx-LaFrance C; Majchrzak MJ; Ramirez AD; Schmidt K; Seymour PA; Siuciak JA; Tingley FD; Williams RD; Verhoest PR; Menniti FS
    J Pharmacol Exp Ther; 2008 May; 325(2):681-90. PubMed ID: 18287214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington's Disease.
    Cardinale A; Paldino E; Giampà C; Bernardi G; Fusco FR
    PLoS One; 2015; 10(8):e0134482. PubMed ID: 26252217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A.
    Harada A; Suzuki K; Miura S; Hasui T; Kamiguchi N; Ishii T; Taniguchi T; Kuroita T; Takano A; Stepanov V; Halldin C; Kimura H
    Nucl Med Biol; 2015 Feb; 42(2):146-54. PubMed ID: 25451212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.